Nebulised Heparin for Acute Lung Injury
Author Information
Author(s): Barry Dixon, John D Santamaria, Duncan J Campbell
Primary Institution: St Vincent's Hospital
Hypothesis
Can nebulised heparin limit damage from fibrin deposition in patients with acute lung injury?
Conclusion
Nebulised heparin is feasible for use in mechanically ventilated patients with acute lung injury and does not cause serious adverse events.
Supporting Evidence
- Administration of nebulised heparin was feasible and did not cause serious adverse events.
- Higher doses of nebulised heparin increased APTT levels.
- Further larger trials are needed to confirm safety and efficacy.
Takeaway
Doctors tested a new treatment using nebulised heparin for patients with lung problems, and it seemed safe to use.
Methodology
An open-label phase 1 trial with four escalating doses of nebulised heparin was conducted on 16 ventilated patients with acute lung injury.
Potential Biases
Potential bias due to the open-label design and small sample size.
Limitations
The study lacked a control group, had a small sample size, and was conducted over a short duration.
Participant Demographics
Mean age of participants was 58 years, with a mix of genders and various causes of acute lung injury.
Statistical Information
P-Value
0.06
Statistical Significance
p=0.09
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website